ClinicalTrials.gg
WithdrawnNCT06378528Updated Nov 6, 2026

Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)

An Early Phase 1 interventional study of Ketamine and SmartSleep EEG recording headband in Posttraumatic Stress Disorder, sponsored by University of Wisconsin, Madison. Withdrawn. Open to participants aged 15 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Wisconsin, Madison · Early Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Budgeting/funding
Updated Nov 6, 2026Now WithdrawnNo longer in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
15 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing ketamine in Stress Disorders, Post-Traumatic — 4 open to participants now, 6 under way, none of them phase 3. Ketamine · Stress Disorders, Post-Traumatic.

Enrollment
21st of 23
0 · median 30
Started
2026
with 1 other
Phase 1
3 of 23
none open now
Registered
19th of 23
by date

Among the 23 studies testing ketamine in Stress Disorders, Post-Traumatic, this one is the 21st largest by enrollment, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 19th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 23 studies testing ketamine in Stress Disorders, Post-Traumatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 15 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing ketamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The objectives of this study are to investigate the feasibility, tolerability, and preliminary efficacy of repeated ketamine-assisted psychotherapy sessions in adolescents with severe posttraumatic stress disorder. The study will enroll adolescents with a current diagnosis of posttraumatic stress disorder (PTSD) to complete three intravenous ketamine administrations accompanied by a psychotherapy session over the span of six weeks. All participants will complete an initial set of preparatory sessions, and each dosing session will be followed by three to six hours of integration sessions. Finally, participants will complete 7 nights of at-home sleep recordings. The investigators hypothesize that this protocol will be well-tolerated by adolescents and that patients will experience decreases in PTSD symptom severity at follow-up.

Read the detailed description

Primary Objective:

  • Characterize safety and adverse events associated with repeated ketamine-assisted psychotherapy in adolescents with PTSD.

Secondary Objectives:

  • Evaluate initial feasibility of recruitment and retention of adolescents with PTSD.
  • Explore potential impacts of ketamine-assisted psychotherapy on PTSD symptom severity at follow-up
03

Conditions studied

  • Posttraumatic Stress Disorder
04

Who can participate

Ages eligible
15 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 15-17 years old, inclusive
  • At baseline, meet threshold for Diagnostic and Statistical Manual () criteria for current PTSD as determined by the CAPS-CA.
  • Medically and neurologically healthy on the basis of physical examination, medical history, and the clinical judgement of the evaluating study medical provider
  • Must agree to inform the investigators within 48 hours of any emergent medical conditions and procedures
  • If of , must have a negative pregnancy test at study entry and prior to each KAP dosing session, and must agree to use adequate through 10 days after the last KAP dosing session.
  • Must agree not to participate in any other interventional clinical trials during the duration of the study
  • Must be willing to comply with all study procedures
  • A primary parent or guardian is willing to provide
  • Are fluent in or predominantly speaking and reading in English

Exclusion criteria

Exclusion Criteria:

  • Caregiver or adolescent is unwilling or unable to give adequate
  • Are likely, in the investigator's opinion and via observation during the Preparatory Period, to be re-exposed to their index trauma or other significant trauma, lack social support, or lack a stable living situation during study participation.
  • Any finding(s), based on the screening process, that the PI feels would make the study unsuitable for the participant.
  • Current diagnosis of or history of a psychotic disorder, bipolar disorder, or autism spectrum disorder diagnosed by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS) interview and clinician judgement. No other co-morbid disorders are exclusionary.
  • Intellectual disability (IQ\<70) per medical history
  • History of moderate to severe substance use disorder, as determined by the KSADS and/or clinician judgement (excluding tobacco), or active substance use (including current alcohol use or positive urine toxicology)
  • Any prior exposure to sub-anesthetic doses of ketamine (including prior research or clinical psychiatric treatment with ketamine and/or recreational use)
  • Any participant presenting current serious suicide risk, as determined through the KSADS, responses to Columbia Suicide Severity Rating Scale (C-SSRS), and/or clinical judgment of the investigator, will be excluded; however, history of suicide attempts prior to enrollment is not an exclusion.
  • Would present a serious risk to others as established through clinical interview and contact with treating physician.
  • Current use benzodiazepines, opiates, or lamotrigine, which are hypothesized to interfere with ketamine's mechanism of action
  • High blood pressure (BP) at the time of screening, defined by the Centers for Disease Control and Prevention (CDC) to be BP greater than 130/80.
  • Persons who have previously received ketamine therapeutically or taken it recreationally.
  • Are pregnant, nursing, or are able to become pregnant and are not practicing an effective means of .
  • Persons who are known to have a to ketamine
  • Participants that are deemed not to be medically and neurologically healthy on the basis of physical examination, medical history, and the clinical judgement of the Study Medical Provider or qualified designee in order to participate.

    • Examples of medical rule-outs include but are not limited to: unstable hypertension, recent severe neurologic injury, a history or current signs/symptoms of liver or renal insufficiency, and current diagnoses of cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disorders that are deemed based on investigator judgement.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Adolescents with Severe PTSD

    Drug: Ketamine · Device: SmartSleep EEG recording headband

Interventions

  • 3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks

    Also known as: Ketamine Assisted Psychotherapy

  • DeviceSmartSleep EEG recording headband

    Participants will complete 7 nights of at-home sleep recordings for exploratory analysis

06

What researchers measure

Primary outcomes

  1. Summary of Adverse Events Attributable to Ketamine Administration

    Degree of adverse effects (AEs) attributable to ketamine administration as categorized according to the abbreviated (six-item) Clinician-Administered Dissociative States Scale (CADSS-6), which assesses situation-dependent dissociative states, and the Systematic Assessment for Treatment Emergent Events (SAFTEE-GI), which uses a standardized general (SAFTEE-GI) inquiry of physical/health problems and possible treatment-emergent side effects. The SAFTEE-GI will be administered during the preparatory period, at every KAP dosing session, integration, and endpoint assessment visit, the CADSS-6 will be administered at every KAP dosing session and during each integration period. Reported here are a list of AEs attributed to KAP Administration with count of participants experiencing them.

    Time frame: through the last study visit, up to 10 weeks

Secondary outcomes

  1. Number of Participants Adhering to the Study Protocol

    Study protocol adherence for preparation, dosing, and follow-up visits.

    Time frame: up to 10 weeks

  2. Number of Visits Completed Throughout the Study Duration

    There are approximately 16 study visits from screening through one month follow up.

    Time frame: up to 10 weeks

Other outcomes

  1. Changes in PTSD symptom severity as measured by the Clinician Administered PTSD Scale Child/Adolescent Version (CAPS-CA)

    The CAPS-CA is a well-validated instrument in adolescent populations and is used often in pediatric clinical trials. This outcome will assess the current severity of overall PTSD symptomatology. Assessments of this endpoint will occur prior to any preparatory sessions and again at a 1-month follow-up. Scores indicate a PTSD severity rating from 0 (absent), 1 (mild), 2 (moderate), 3 (severe), or 4 (extreme).

    Time frame: baseline and 1 month follow up (at up to 10 weeks on study)

  2. Exploratory Measurements: Change waveform recorded with Philips SmartSleep headband, measured in Hz

    During the first KAP session week, sleep will be recorded for seven nights (3 nights prior to the KAP session, night of KAP session, and 3 nights after KAP session) using the Philips SmartSleep recording headband. The SmartSleep device collects real-time EEG data. The EEG signals are acquired at 1000 Hz, high-pass filtered using a single pole filter (0.3 Hz cutoff frequency), notch filtered at 50 Hz and 60 Hz to remove power-line noise, and down-sampled to 250 Hz for real-time, onboard sleep scoring.

    Time frame: 7 consecutive nights surrounding the first KAP session, during study week 2

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 22, 2024
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Withdrawn
changed Nov 6, 2026
Sites
1 site removed; no longer in United States
Show 1 removed
  • University of Wisconsin · Madison, United States
Nov 6, 2026
Enrollment
5 (estimated)→0 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Suspended→Withdrawn
    1 site removed; no longer in United States
    Show 1 removed
    • University of Wisconsin · Madison, United States
    Enrollment 5 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06378528
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Christopher Nicholas, PhD
principal investigator · University of Wisconsin, Madison

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion